Pharmacokinetic endpoints included the total exposure of IDeg , ie the area under the IDeg serum concentration curve during one dosing interval at steady state ( AUC ( IDeg , , SS ) ) ( = 0-24 h , equal to one dosing interval ) and the maximum IDeg serum concentration at steady state ( C ( max , IDeg , SS ) ) .